Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ERN1 | O75460 | 2/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.33 |
| ▸ | CES2 | O00748 | 2/20 | 0.32 |
| ▸ | CES1 | P23141 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5747733 | 0.84 | ALDH1A1 (0.39) | ALDH1A1KDM4EERN1PTPN1NFE2L2 | |
| SCHEMBL29954838 | 0.80 | KDM4E (0.39) | ALDH1A1KDM4EERN1PTPN1 | |
| SCHEMBL1956935 | 0.80 | KDM4E (0.39) | ALDH1A1KDM4EERN1PTPN1 | |
| SCHEMBL22654821 | 0.78 | CA12 (0.32) | ERN1MEN1KMT2ALMNATHRB | |
| SCHEMBL18464860 | 0.77 | ERN1 (0.37) | ALDH1A1KDM4EERN1PTPN1CES2 | |
| SCHEMBL15428103 | 0.76 | SRC (0.43) | ALDH1A1KDM4EERN1MAPTMEN1 | |
| SCHEMBL22686751 | 0.76 | ERN1 (0.52) | ALDH1A1KDM4EERN1PTPN1MAPT | |
| SCHEMBL22687434 | 0.76 | ALOX5AP (0.36) | ALDH1A1KDM4EERN1PTPN1CES2 | |
| SCHEMBL4363014 | 0.73 | ERN1 (0.46) | ALDH1A1KDM4EERN1PTPN1NFE2L2 | |
| SCHEMBL29957006 | 0.73 | ERN1 (0.46) | ALDH1A1KDM4EERN1PTPN1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913770-B2 | Mertansine polypeptide conjugates | VISION GLOBAL HOLDINGS LIMITED (CN) | 2021-02-09 | — | — | US | disclosed |
| US-20200361988-A1 | MERTANSINE POLYPEPTIDE CONJUGATES | VISION GLOBAL HOLDINGS LIMITED (HK) | 2020-11-19 | — | — | US | disclosed |
| US-9837622-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-05 | — | — | US | disclosed |
| US-9837622-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-05 | — | — | US | disclosed |
| US-20150263297-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| US-20150263297-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| WO-2014008982-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361988-A1 | MERTANSINE POLYPEPTIDE CONJUGATES | NGLY1, ANPEP, VIP | ALDH1A1 3769/4885KDM4E 3679/4885ERN1 4075/4885 |
| US-10913770-B2 | Mertansine polypeptide conjugates | NGLY1, ANPEP, VIP | ALDH1A1 3769/4885KDM4E 3679/4885ERN1 4075/4885 |
| US-20150263297-A1 | Metal Complexes | SOD1, AP1M1, AP3M1 | ALDH1A1 3721/4885KDM4E 3816/4885ERN1 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.